Healthcare provider profile · identity verified

David Shrake, D.O.

Family Practice · WOODBURY, MN · NPI 1003295726

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	584	156
Lisinopril	Lisinopril	256	74
Amlodipine Besylate	Amlodipine Besylate	235	62
Rosuvastatin Calcium	Rosuvastatin Calcium	208	66
Omeprazole	Omeprazole	203	57
Levothyroxine Sodium	Levothyroxine Sodium	200	44
Losartan Potassium	Losartan Potassium	173	47
Hydrochlorothiazide	Hydrochlorothiazide	166	46
Trazodone Hcl	Trazodone Hcl	124	35
Metoprolol Succinate	Metoprolol Succinate	110	34
Gabapentin	Gabapentin	109	35
Metformin Hcl Er	Metformin Hcl	101	30
Fluticasone Propionate	Fluticasone Propionate	94	38
Metformin Hcl	Metformin Hcl	93	28
Simvastatin	Simvastatin	82	23
Tamsulosin Hcl	Tamsulosin Hcl	74	26
Allopurinol	Allopurinol	73	23
Pantoprazole Sodium	Pantoprazole Sodium	62	16
Duloxetine Hcl	Duloxetine Hcl	60	11
Carvedilol	Carvedilol	57	17
Furosemide	Furosemide	56	18
Albuterol Sulfate Hfa	Albuterol Sulfate	55	32
Warfarin Sodium	Warfarin Sodium	55	12
Jardiance	Empagliflozin	46	13
Famotidine	Famotidine	44	15
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	44	13
Montelukast Sodium	Montelukast Sodium	43	suppressed
Xarelto	Rivaroxaban	43	12
Alendronate Sodium	Alendronate Sodium	42	15
Escitalopram Oxalate	Escitalopram Oxalate	42	13
Doxazosin Mesylate	Doxazosin Mesylate	40	suppressed
Bupropion Hcl Sr	Bupropion Hcl	39	12
Glipizide	Glipizide	39	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	38	11
Sertraline Hcl	Sertraline Hcl	37	suppressed
Bupropion Xl	Bupropion Hcl	36	11
Tizanidine Hcl	Tizanidine Hcl	36	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	35	11
Pravastatin Sodium	Pravastatin Sodium	35	suppressed
Trulicity	Dulaglutide	35	suppressed
Clopidogrel	Clopidogrel Bisulfate	33	suppressed
Eliquis	Apixaban	33	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	31	suppressed
Azelastine Hcl	Azelastine Hcl	29	11
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	26	suppressed
Ezetimibe	Ezetimibe	24	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	24	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	23	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	23	suppressed
Prednisone	Prednisone	23	22
Triamcinolone Acetonide	Triamcinolone Acetonide	23	16
Midodrine Hcl	Midodrine Hcl	22	suppressed
Finasteride	Finasteride	21	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	21	suppressed
Diclofenac Sodium	Diclofenac Sodium	20	suppressed
Propranolol Hcl	Propranolol Hcl	20	suppressed
Chlorthalidone	Chlorthalidone	18	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	18	suppressed
Naltrexone Hcl	Naltrexone Hcl	18	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	18	suppressed
Ozempic	Semaglutide	18	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	17	suppressed
Mirtazapine	Mirtazapine	17	suppressed
Pregabalin	Pregabalin	17	suppressed
Breo Ellipta	Fluticasone/Vilanterol	16	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	16	suppressed
Valsartan	Valsartan	16	suppressed
Ventolin Hfa	Albuterol Sulfate	16	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Soliqua 100-33	Insulin Glargine/Lixisenatide	15	suppressed
Myrbetriq	Mirabegron	14	suppressed
Clotrimazole	Clotrimazole	13	12
Risperidone	Risperidone	13	suppressed
Irbesartan	Irbesartan	12	suppressed
Lovastatin	Lovastatin	12	suppressed
Potassium Chloride	Potassium Chloride	12	suppressed
Incruse Ellipta	Umeclidinium Bromide	11	suppressed
Linzess	Linaclotide	11	suppressed
Methylphenidate Er	Methylphenidate Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error